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Abstract
Background: Previously two prediction rules identifying children at risk of hearing loss and academic or behavioral
limitations after bacterial meningitis were developed. Streptococcus pneumoniae as causative pathogen was an
important risk factor in both. Since 2006 Dutch children receive seven-valent conjugate vaccination against S.
pneumoniae. The presumed effect of vaccination was simulated by excluding all children infected by S. pneumoniae
with the serotypes included in the vaccine, from both previous collected cohorts (between 1990-1995).
Methods: Children infected by one of the vaccine serotypes were excluded from both original cohorts (hearing
loss: 70 of 628 children; academic or behavioral limitations: 26 of 182 children). All identified risk factors were
included in multivariate logistic regression models. The discriminative ability of both new models was calculated.
Results: The same risk factors as in the original models were significant. The discriminative ability of the original
hearing loss model was 0.84 and of the new model 0.87. In the academic or behavioral limitations model it was
0.83 and 0.84 respectively.
Conclusion: It can be assumed that the prediction rules will also be applicable on a vaccinated population.
However, vaccination does not provide 100% coverage and evidence is available that serotype replacement will
occur. The impact of vaccination on serotype replacement needs to be investigated, and the prediction rules must
be validated externally.
Background
About 5 per 100,000 children suffer from bacterial
meningitis (BM) in the Netherlands per year [1]. BM is
still a serious disease with a mortality rate of 5%, despite
antibiotic treatment and advances in care of critically ill
patients [2]. Approximately 15-20 percent of BM survi-
vors develop severe acute or long term sequelae such as
epilepsy, hydrocephalus or hearing loss. More subtle
adverse outcomes such as cognitive or behavioral limita-
tions are present in 20-30 percent of the children [3-7].
Some of these more subtle limitations are recognized in
an early phase after the BM, but a major group has sub-
stantial delay in the detection of these problems. Early
detection of sequelae and adequate treatment or follow
up is of major importance since it may prevent worsen-
ing of symptoms and development of secondary
problems.
We have previously developed two prediction rules to
identify children at risk of developing hearing loss and
academic or behavioral limitations after BM. These pre-
diction rules consist of clinical variables which can be
obtained during admission. The following variables were
identified as risk factors for developing hearing loss:
duration of symptoms prior to admission, absence of
petechiae, cerebral spinal fluid (CSF) glucose level,
Streptococcus pneumoniae as causative pathogen and
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limitations included: gender, birth weight, educational
level of the father, S. pneumoniae as causative pathogen,
CSF leukocyte count, delay between admission and the
start of antibiotics, the use of dexamethasone, seizures,
and the duration of fever during admission. The ratio-
nale and design of the studies in which the prediction
rules were developed have been extensively described in
earlier manuscripts [5,6].
In both our prediction rules S. pneumoniae as causa-
tive pathogen is an important risk factor. Since June
2006 all Dutch newborn children receive a seven-valent
conjugate vaccine (PCV-7) against this pathogen (sero-
types 4,6B,9V,14,18C,19F,23F) on the age of 2,3,4 and
11 months.
Observations in other countries which introduced this
vaccine earlier showed major decrease of BM and other
infections caused by S. pneumoniae with the serotypes
included in the vaccine. An increase in the incidence of
the not included serotypes 19A, 6C, 22F and 15 was
also observed [8-13]. As a result the population of chil-
dren who might develop BM after vaccination is
expected to be smaller and with different distribution of
pneumococcal serotypes than the population on which
the two prediction rules have been based. The aim of
this study was to evaluate whether the existing predic-
tion rules are also still applicable on a vaccinated
population.
Methods
This study consists of secondary data analyses of pre-
viously collected data, used to develop the prediction
rules for developing hearing loss and academic or beha-
vioral limitations. Approval for use of this data was
obtained from the entitled researchers. The construction
of these rules has been described extensively in the ori-
ginal publications [5,6]. In short, the design was as fol-
lows: all Dutch children born between January 1986 and
December 1994 that recovered from BM caused by
Neisseria meningitidis, S. pneumoniae, Streptococcus
agalactiae, Escherichia coli or Listeria monocytogenes
between January 1990 and December 1995 were eligible
for the study. These children were selected from the
files of the Netherlands Reference Laboratory for BM
which collects strains and data from approximately 80%
of all Dutch meningitis cases [1]. The diagnosis of BM
was confirmed in CSF by culture of bacteria or by
demonstrating bacterial antigens with latex agglutina-
tion. All patients with a complex onset of BM (defined
as: meningitis secondary to immunodeficiency states,
central nervous system surgery, cranial trauma or cere-
brospinal fluid shunt infection, or relapsing meningitis),
pre-existing cognitive or behavioral problems or severe
handicaps were excluded [5,6].
Sixteen hundred and five children treated in 110 dif-
ferent Dutch hospitals met the criteria for inclusion.
The pediatricians of these hospitals were asked to send
the parents (or guardians) a standard letter requesting
their participation. The parents who returned informed
consent were sent screening questionnaires about
health, learning and behavior, and were asked permis-
sion to study the medical records of their child.
Finally, 628 children were included in the cohort
regarding hearing loss and 674 children in the cohort
used for the development of the rule predicting aca-
demic or behavioral limitations [5,6].
Hearing loss was defined as a perceptive loss of >25
dB and was based on information from questionnaires
and medical records. A total of 43 of the remaining 628
children were identified as having hearing loss. Informa-
tion on the risk factors included in the prediction rule
for hearing loss, was extracted from the medical records
[5].
Academic or behavioral limitations were identified in
two steps. The first step was based on parental percep-
tion on learning and behavior studied by two question-
naires. Based on the scores on the questionnaires the
674 children were divided into two groups: one with
children with parents with complaints on learning and
behavior (n = 134, 20%) and one with children with par-
ents without these complaints (n = 540, 80%). For the
second step a nested case-control study of 201 children
was constructed. Therefore a random sample from both
groups was drawn: 100 children from the group with
and 101 from the group without suspected problems.
The medical records of these 201 children were studied
to identify the risk factors included in the prediction
rule for academic or behavioral limitations. Exploration
of these records sometimes provided new information
on medical history, resulting in extra patients meeting
exclusion criteria. Therefore another 19 of the 201 chil-
dren were excluded, leaving a total of 182 children in
the cohort (89 with suspected problems based on paren-
tal perception, 93 without). These 182 children were
extensively tested on academic performance using a
Academic Achievement Test (AAT) and on behavioral
functioning with the Child Behavior Checklist (CBCL)
[14]. Out of 182 children, 84 were identified as having
academic or behavioral limitations, leaving 98 children
without limitations [6].
Based on the two primary outcome measures “hearing
loss” and “academic or behavioral limitations” and the
risk factors found, the two prediction rules were devel-
oped using a multivariable logistic regression model.
Potential risk factors were studied resulting, as men-
tioned in the introduction paragraph, in 5 independent
risk factors in the hearing loss prediction model and in
9 factors in the prediction rule for academic or
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flow charts of the inclusion and assessment.
Statistical analysis
We simulated the presumed effect of the vaccination by
excluding all children who were infected by S. pneumo-
niae with one of the seven vaccine serotypes
(4,6B,9V,14,18C,19F,23F) from both cohorts. Twenty six
(9 with and 17 without limitations) of 182 children of
the academic or behavioral limitations cohort and 70
(12 with and 58 without hearing loss) of 628 children
from the hearing loss cohort were excluded. Two new
prediction rules were calculated using this two adjusted
cohorts.
Univariate logistic regression analysis was used to
assess the effects of all original potential risk factors col-
lected in the adjusted cohorts. Continuous variables
were dichotomized when a linear relationship with the
outcome could not be assumed. All variables with a p-
value of less than 0.20 were included in a multivariate
logistic regression model. This first selection step was
needed because the number of potential risk factors
compared to the group size was too large. The predic-
tion models were developed using a forward selection
method using a threshold p-value of 0.10 for variables
t ob ei n c l u d e di nt h em o d e l s .T h ea r e au n d e rt h ec u r v e
(AUC) of the receiver operating curve (ROC) was calcu-
lated to assess the discriminative ability of both
prediction rules. A score for each risk factor was deter-
mined by dividing the (original, not rounded) regression
coefficient of each variable in the model by the smallest
regression coefficient of the model, multiplied by 10 and
rounding off to the nearest integer. From each child a
score was calculated by filling in the values from his or
her risk factors in the prediction rules. These values are
summarized in a table and a cut off score for having a
high risk of developing hearing loss or academic or
behavioral limitations was chosen to obtain the highest
discriminative ability between groups. All analyses were
carried out using SPSS statistical software edition 14.0
(SPSS inc, Chicago, US).
Results
Hearing loss
The regression coefficients, odds ratios and the contri-
bution to the score of the five independent predictors of
hearing loss after recovery from BM in childhood are
presented in Table 1. These are the same five predictors
that were also found in the previous prediction model
[5], although the variable “duration of symptoms” has
now been divided into three categories instead of two
(namely < 1 day; 1-2 days, and > 2 days) because it was
not significantly correlated with the development of
hearing loss when divided in two categories (p = 0.12).
S. pneumoniae still remained an important risk factor
for children who were infected by a different serotype
Eligible: 
 
n=1605 
 
Included: 
 
n=628 in original cohort 
n=558 after removal of vaccine  
         serotypes 
Hearing loss: 
 
n=43 in original cohort 
n=31 after removal of vaccine  
         serotypes 
 
No hearing loss:
 
n=585 in original cohort 
n=527 after removal of vaccine  
           serotypes 
 
- request for participation pediatricians 
- informed consent parents 
parental perception questionnaires 
Figure 1 patient flow chart for “hearing loss”.
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The regression coefficients and also the risk scores
assigned to each variable were only slightly different
from the previous prediction rule (AUC of the regres-
sion model after: 0.87 (95% confidence interval 0.82-
0.93), versus 0.84 (95% confidence interval 0.78-0.91) in
the original cohort) [5]. Table 2 shows a summary of
the computed risk score for each child using the predic-
tion rule.
When we applied the newly developed prediction rule
on the post-pneumococcal vaccination cohort we could
predict all children with hearing loss by using a cut off
score of ≥ 10. No children with hearing loss had a score
below 10; this means that a patient is at risk when one
of the predictors is present. Three hundred and twenty
one (82+84+140+15) of the total cohort of 558 children
(58%) had a risk score ≥ 10, and were selected as being
at risk of developing hearing loss. In the previous
Eligible: 
 
n=1605 
Included: 
 
n=674 
Complaints: 
 
n=134 
No complaints: 
 
n=540 
 
n=100 
 
 
n=101 
 
 
n=89 
 
 
n=93 
 
With limitations: 
 
n=84 in original cohort 
n=75 after removal of vaccine  
         serotypes 
Without limitations: 
 
n=98 in original cohort 
n=81 after removal of vaccine  
         serotypes 
Random sample
Exclusion criteria
assessment of academic 
achievement and behavior 
n=72 n=63 n=26 n=21
- request for participation pediatricians 
- informed consent parents 
parental perception questionnaires 
Figure 2 patient flow chart for “academic or behavioral limitations”.
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both rules have equally strong abilities to screen for
hearing loss. Using this cut off score of ≥ 10, 290 (80
+80+124+6) of 527 children (55%) without hearing loss
are falsely predicted as children with hearing loss. Figure
3 gives an overview of the percentages of children posi-
tively and falsely predicted as children with hearing loss
using different cut off points.
Academic or behavioral limitations
Table 3 presents the predictors which were indepen-
dently associated with the risk of developing academic
or behavioral limitations after recovery from BM in
childhood. All nine risk factors used in the original pre-
diction rule of Koomen et al. remained significant [6].
However, the most striking differences compared with
the previous model were the regression coefficients of
the risk factor “delay of more than 6 hours between
admission and start of antibiotics” which changed from
0.9 to 2.4 and the regression coefficient of birth weight
≤ 3000 gram which changed from 0.8 to 1.5. In both the
old and new prediction rule, low birth weight was asso-
ciated with a higher risk of developing limitations. The
AUC of our new regression model after was 0.84 (95%
confidence interval 0.78-0.90) which is comparable with
the AUC of the model of the original cohort of Koomen
et. al. (0.83;95% confidence interval 0.77-0.89) [6].
Table 4 shows a summary of the computed risk score
for each child using the prediction rule. To demonstrate
how the prediction rule for academic or behavioral lim-
itations can be used we here give an example of a male
patient (risk score: +38), with a birth weight of 3500
gram (risk score:0), a father with middle education level
(risk score: +36), with S. pneumoniae as causative patho-
gen (risk score: +42), and a leukocyte count of 20000/
cells in the CSF (risk score: -20). He had a delay of 8
hours between admission and start of antibiotics (risk
score: +53), and no dexamethasone was used (risk score:
0). He developed no seizures (risk score: 0), nor pro-
longed fever (risk score: 0). His total risk score is than
149 and thus he has a high risk of developing academic
or behavioral limitations.
When we applied the newly developed prediction rule
on the post-pneumococcal vaccination cohort, using a
c u to f fs c o r eo f>6 4 , 7 5w ew e r ea b l et op o s i t i v e l yp r e -
dict 65 (18+30+17) of 75 children (87%) with limita-
tions. This means that 103 (48+38+17) of the total of
166 children (62%) with a risk score > 64,75 are selected
as possibly having limitations to reach 87% of positive
predictions, whereas 38 (30+ 8 + 0 )o f9 1c h i l d r e n( 4 2 % )
without limitations are falsely predicted as children with
limitations. With the previous prediction rule, 76% of
the children with limitations could be positively pre-
dicted by selecting 38% of all children as having a high
Table 1 Independent predictors of hearing loss after bacterial meningitis.
Variable Regression coefficient Odds ratio (95% CI) Contribution to risk score
Duration of symptoms
< 1 day RC 0
1-2 days 0.8 2.3 (0.7-7.2) 10
> 2 days 1.0 2.8 (1.0-8.0) 13
Absence of petechiae 2.4 11.0 (2.7-45.4) 29
CSF glucose level < 0.6 mmol/L 1.0 2.8(1.2-6.6) 13
S. Pneumoniae 1.1 3.2 (1.2-8.5) 14
(Transient) ataxia 3.3 28.4 (5.7-142.3) 40
Risk score = 10 × duration of symptoms 1-2 days + 13 × duration of symptoms > days + 29 × absence of petechiae + 13 × CSF glucose leven < 0.6 mmol/L +
14 × S. Pneumoniae + 40 × (transient) ataxia
AUC of the regression model:: 0.87 (95% confidence interval 0.82-0.93)
RC = reference category. For final risk score add all separate risk factors per child.
RC = reference category; CSF = Cerebrospinal fluid.
Table 2 Number of children with and without hearing loss across categories of the risk score. Values represent
numbers (percentages).
Risk score Children in the cohort n = 558(%),
cumulative n(%)
Children with hearing loss n = 31 (%),
cumulative n(%)
Children without hearing loss n = 527 (%),
cumulative n(%)
0-9 237 (42) 0 (0) 237 (45)
10-23 82 (15) 319 (57) 2 (6) 80 (15) 317 (60)
24-39 84 (15) 403 (72) 4 (13) 6 (19) 80 (15) 397 (75)
40-56 140 (25) 543 (97) 16 (52) 22 (71) 124 (24) 521 (99)
≥57 15 (3) 558 (100) 9 (29) 31 (100) 6 (1) 527 (100)
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for limitations. Figure 4 gives an overview of the percen-
tages of children positively and falsely predicted as chil-
dren with limitations using different cut off points.
Discussion
We studied the effect of the introduction of a seven
valent conjugate pneumococcal vaccine on two previous
developed prediction rules for hearing loss and academic
or behavioral limitations in the Netherlands. The pre-
sumed effect of vaccination was simulated by excluding
all children infected by S. pneumoniae with the sero-
types included in the vaccine, from both previous col-
lected cohorts. After calculating two new prediction
rules we found that all original risk factors remained
significant. So it can be assumed that the original pre-
diction rules will also be applicable on a vaccinated
population. The discriminative ability of both prediction
rules remained as high as observed in the previous stu-
dies of Koomen et al. [5,6]. The risk factor “S. pneumo-
niae as causative pathogen” remained significant. This
could be explained by the fact that the children infected
by some of the non-vaccinated serotypes of this bacter-
ium had a less favorable outcome than children infected
by the PCV-7 serotypes or other pathogens [15],
although there is not much evidence available for this
phenomenon.
Some limitations of this study should be acknowl-
edged. First item to address originates from the original
prediction rules. From the cohort of 1605 children eligi-
ble, most children were excluded because the pediatri-
cians or the parents did not want to participate.
Although most of the basic patient characteristics as
sex, age, and causative pathogen were very similar in
both the original cohort and the included children, sug-
gesting that these cohorts were representative for the
original BM population, exclusion bias is possible.
Further, the outcome measure “academic or behavioral
limitations” was prospectively and extensively tested, but
Figure 3 positively vs falsely predicted as children with
hearing loss using different cut off points. Legend: ▼ =%
children in the total cohort (100% = 558 children). Ο = % positively
predicted children with hearing loss (100% = 31 children). □ =%
falsely predicted children without hearing loss (100% = 527
children)
Table 3 Independent predictors of academic or behavioral limitations after bacterial meningitis.
Variable Regression coefficient Odds ratio (95% CI) Contribution to risk score
Male gender 1.7 5.8 (2.3-14.5) 38
Birth weight ≤3000 gram 1.5 4.5 (1.7-12.1) 33
Educational level father
a
Lower education 2.0 7.3 (2.1-25.3) 43
Middle education 1.7 5.3 (1.6-17.1) 36
Higher education RC 0
S. pneumoniae as causative pathogen 1.9 6.9 (1.7-28.3) 42
CSF leukocyte count/10000 cells (/3 mm
3) -0.5 0.6 (0.4-0.9) -10
Delay of more than 6 hours between admission and start of antibiotics 2.4 11.2 (1.6-76.4) 53
Dexamethasone
≤ 2 days 1.0 2.8 (0.5-14.1) 22
> 2 days -0.8 0.4 (0.2-1.2) -19
no RC 0
Seizures treated with anticonvulsive therapy -2.9 0.1 (0.0-0.4) -62
Prolonged fever (> 9 days) 3.6 37.8 (3.3-435.6) 79
Score = 38 × Male gender + 33 × Birth weight ≤ 3000 gram + 43 × lower educational level father + 36 × middle educational level father + 42 × S. Pneumoniae -
10 × CSF leukocyte count/10000 cells (/3 mm
3) + 53 × delay of more than 6 hours between admission and start of antibiotics + 22 × Dexamethasone ≤ 2 day -
19 × Dexamethasone > 2 days - 62 × Seizures treated with anticonvulsive therapy + 79 × prolonged fever.
AUC of the regression model: 0.84 (95% confidence interval 0.78-0.90)
RC = reference category; CSF = Cerebrospinal fluid.
a Lower education = lower administrative or technical education (or less), middle education = secondary education, higher education = college or university
education.
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possibility that some mild hearing problems were missed
[5,6]. These limitations of the original studies also apply
to the updated rules in this manuscript.
Second, the sample sizes included in the analyses are
relatively small for developing new prediction models.
General rules of thumb recommend at least ten cases
per included variable. So the recommend number of
children with hearing loss or limitations was 50 and 90
respectively, whereas our cohorts included 31 and 75
children with hearing loss or limitations, respectively.
The variable ataxia included in the rule for predicting
hearing loss and the variable prolonged fever in the rule
for limitations had a very high Odds Ratio and a very
large confidence interval. This may reflect this power
problem. As mentioned before, the regression coefficient
of the variable “delay of more than 6 hours between
admission and start of antibiotics” changed from 0.9 tot
2.4, with also relatively high Odds Ratio and a large con-
fidence interval. This striking difference may also be a
result from low power.
The next issue concerns the applicability of this new
constructed rule in clinical practice. Although we believe
that the methodology and statistical analyses used are
adequate, we do realize that the original rules are not
externally validated yet. It is known that prediction rules
might act significantly different when applied to a new
cohort, making external validation and, if necessary
updating, essential [16-19]. External validation of the
original models is performed, but to come to an optimal
result for the new situation, a cohort with vaccinated
children should be constructed. But, at this moment the
number of vaccinated children in the Netherlands is
relatively small and follow up time is short, making
external validation a difficult procedure. Further, the
acceptable proportion of children with problems that
were not predicted is disputable, making it difficult to
recommend cut off points of the scores in clinical prac-
tice. Regarding hearing loss, we believe it is justifiable to
say that hearing loss may not be missed at all, proposing
a cut off score of ≥10. Regarding academic and beha-
vioral limitations, the proportion of positively predicted
children is 87% using a cut off point of 64,75, decreasing
to 63% with a higher cut off point (figure 4). We believe
this is a reasonable result, but practitioners may find
this score to liberal.
Final point of discussion is the fact that the vaccine
does not provide full coverage, although rates differ
between countries and age-groups [8,9,20,21], and that
serotype replacement is likely. This issue and an
increase of invasive infections with non-vaccine sero-
types has been observed in other countries [9-12,22].
The actual effect of vaccination and the amount of sero-
type replacement are unpredictable and it can take
many years before a new balance in serotype prevalence
is established [12,23]. Because BM has most impact in
young children, especially those under the age of 1 year,
vaccination is most relevant for this age group. It is
therefore especially important to validate and update the
prediction rules in this age group in future studies
[16,19]. When validated, effort should be shifted to
determine how to implement the clinical use of the pre-
diction rules and thereby improve clinically outcome for
BM surviving children.
Table 4 Number of children in the cohort with and without academic or behavioral limitations across categories of
the risk score. Values represent numbers (percentages).
Risk score Children in the cohort n = 166
(%), cumulative n(%)
Children with academic or behavioral
limitations n = 75(%), cumulative n(%)
Children without academic or behavioral
limitations n = 91(%), cumulative n(%)
≤29 19 (11) 0 (0) 19 (21)
>2 9&≤64,75 44 (27) 63 (38) 10 (13) 34 (37) 53 (58)
> 64,75 &≤94,66 48 (29) 111 (67) 18 (24) 28 (37) 30 (33) 83 (91)
> 94,66 & ≤134,5 38 (23) 149 (90) 30 (40) 58 (77) 8 (9) 91 (100)
> 134,5 17 (10) 166 (100) 17 (23) 75 (100) 0 (0) 91 (100)
Figure 4 positively vs falsely predicted as children with
academic or behavioral limitations using different cut off
points. Legend: ▼ = % children in the total cohort (100% = 166
children). Ο = % positively predicted children with academic or
behavioral limitations (100% = 75 children). □ = % falsely predicted
children without academic or behavioral limitations (100% = 91
children)
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Although incidence is decreasing BM is still a serious
infectious disease with high mortality and morbidity.
The previously developed prediction rules showed that
S. pneumoniae as causative pathogen is an important
risk factor for sequelae. This study concludes that it can
be assumed that the original prediction rules will also
be applicable on a PCV-7 vaccinated population. How-
ever, the vaccine does not provide 100% coverage and
there is evidence that serotype replacement will occur.
The prediction rules need to be validated externally and
further research is needed to investigate the impact of
vaccination on serotype replacement.
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